Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 24, 2015
Juniper and OxSonics Form Cancer Drug Delivery Pact
Author(s)Pharmaceutical Technology Editors
Juniper Pharma Services has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles.
Advertisement
Juniper Pharma Services, formerly known as Molecular Profiles, has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles. These injectable particles, which when used in conjunction with new generation ultrasound devices, can be applied to a range of therapeutic applications including an oncological drug delivery platform called SonoTran. SonoTran is designed to enhance the delivery of anti-cancer drugs deep into and throughout solid tumors.
Colin Story, CEO of OxSonics, said in a
According to Story, OxSonics’ main objective is to commercialize the SonoTran platform, which has the capability to overcome one of the challenges facing solid tumor cancer therapy by delivering drugs throughout tumor volumes including to those areas that lie farthest from blood vessels. Under this agreement, Juniper Pharma Services will manufacture the technology for clinical studies on behalf of OxSonics
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement